CARLSBAD, CA  -  SEPTEMBER 6, 2017 - Amicrobe Inc. closed their fully-subscribed Series C capital raise of $5 million.  Proceeds of the financing will go toward progressing Amicrobe's two lead investigational products, Amicidin-α Surgical Gel and Amicidin-β Solution, and supporting Amicrobe's operations.  Amicrobe's Amicidin-α Surgical Gel is a synthetic protein designed to prevent infection in surgical and traumatic wounds.  Amicidin-β Solution is a synthetic protein designed to treat tissues that are already contaminated or infected.  Together, their purpose is to prevent infections from progressing to serious or life-threatening stages, including sepsis.

​

​